Jenny J. Li, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | Duke University School of Medicine, Durham, North Carolina, US, MD |
| 2012 | Duke University, Durham, North Carolina, US, Biology / Neuroscience, BS |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology/Oncology, Mayo Clinic, Rochester, Minnesota |
| 2016-2019 | Clinical Residency, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas |
Licenses & Certifications
| 2022 | American Board of Internal Medicine - Medical Oncology |
| 2022 | Texas Medical Board |
| 2019 | Minnesota Board of Medicine |
| 2019 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Instructor, Medical Oncology, Mayo Clinic College of Medicine and Science, Rochester, MN, 2021 - 2022
Extramural Institutional Committee Activities
MD Anderson Representative, Elsevier ClinicalPath Gastrointestinal Medical Oncology Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Upper GI clinical multidisciplinary leader, RUSH Non-CRC Multidisciplinary Workgroup, The University of Texas MD Anderson Cancer Center, 2024
Member, Research Committee, Department of Oncology, Mayo Clinic, 2021 - 2022
Member, Clinical Practice Committee, Division of Medical Oncology, Mayo Clinic, 2019 - 2022
Honors & Awards
| 2021 | Top Performing Provider Patient Experience Award, Mayo Clinic |
| 2021 | Virtual Workshop on Methods in Clinical Cancer Research, ASCO/AACR |
| 2013 | Phi Beta Kappa Honor Society, Phi Beta Kappa |
| 2010 - 2011 | Undergraduate Research Support Independent Study Grant, Duke University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Multimodality Therapy for Locally Advanced Esophageal Cancer. Invited. 5th Surgical Oncology Advanced Practitioner (SOAP) Conference. Houston, Texas, US.
Regional Presentations
- 2018. Exploring the metabolism of acetate in early-stage breast cancer. Conference. University of Texas Southwestern Medical Center. Dallas, TX, US.
- 2015. Divergent roles of RAS signaling in embryonal versus alveolar rhabdomyosarcoma. Conference. Duke University School of Medicine. Durham, NC, US.
National Presentations
- 2025. Intraperitoneal chemotherapy in gastric cancer with peritoneal metastases. Invited. 2025 Summit on Gastrointestinal Malignancies, BM.
- 2025. Using the KEYNOTE-811 regimen in locally advanced upper GI cancers. Invited. 2025 Summit on Gastrointestinal Malignancies, BM.
- 2025. MSI-high upper GI malignancies: current treatments and emerging trials. Invited. 2025 Summit on Gastrointestinal Malignancies, BM.
- 2012. Medulloblastoma Oncogene OTX2 Promotes Growth in Other Tumors Via Regulation of MYC, CRX, and Phosphorylation of RB. Conference. Congress of Neurological Surgeons Annual Meeting. Chicago, IL, US.
International Presentations
- 2018. Effective use of electronic medical record (EMR) data in analysis of association between KRAS mutations and depression in colorectal cancer patients. Conference. ASCO Gastrointestinal Cancers Symposium. San Francisco, US.
- 2017. Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients. Conference. ASCO Palliative and Supportive Care in Oncology Symposium. San Diego, US.
Formal Peers
- 2023. Second Line Treatment Landscape in Advanced Gastric Cancer. Houston, Texas, US.
- 2021. Pancreatic and Hepatobiliary Cancers. Rochester, Minnesota, US.
- 2021. Cancer of Unknown Primary. Rochester, Minnesota, US.
- 2020. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. Rochester, Minnesota, US.
- 2020. Aplastic Anemia. Rochester, Minnesota, US.
- 2020. Uveal Melanoma. Rochester, Minnesota, US.
Grant & Contract Support
| Date: | 2024 - 2025 |
| Title: | A Phase 1 Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Mitochondrial Activator of Caspases Mimetic BGB-24714 as Mono and with Combo Therapy in Patients With Solid Tumors |
| Funding Source: | BeiGene Aus Pty Ltd |
| Role: | Principal Investigator-MDACC |
| ID: | 2023-0737 | PID15963 |
| Date: | 2022 - 2023 |
| Title: | Synergistic inhibition of ATM and PARP in pancreatic ductal adenocarcinoma |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| ID: | Young Investigator Award FP17138 |
| Date: | 2021 - 2022 |
| Title: | Department of Oncology Small Grants Program |
| Funding Source: | Mayo Clinic Center for Clinical and Translational Science |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Okui J, Prakash LR, Lyu HG, Morgan RB, Li JJ, Blum-Murphy MA, Ajani JA, Hofstetter WL, Rice DC, Mansfield PF, Swisher SG, Badgwell BD, Ikoma N. Immunotherapy Response in Microsatellite Instability-High Gastroesophageal Adenocarcinoma. JAMA Surg, 2026. PMID: 41984470.
- Sewastjanow-Silva M, Xiao L, Abdelhakeem A, Pabon CM, Yamashita K, Yoshimura K, Badgwell BD, Ikoma N, Meyer L, Sagebiel T, Das P, Li JJ, Ajani JA, Blum-Murphy MA. Survival Benefit of Palliative Oophorectomy for Patients With Ovarian Metastasis From Baseline Metastatic Gastric Adenocarcinoma. J Clin Oncol 43(21):2361-2371, 2025. e-Pub 2025. PMID: 40446172.
- Baerman E, Colli Cruz C, Black S, Gajagowni S, Lu E, Shi K, Li JJ, Liao Z, Richards D, Weston B, Wang Y. Outcomes of Endoscopic Dilation for Radiation Therapy-Related Esophageal Stricture. Curr Treat Options Gastro 23(5), 2025. e-Pub 2025.
- Smith, KE, Acosta-Medina, AA, Dasari, S, Ranatunga, W, Rech, K, Ravindran, A, Young, J, McGarrah, PW, Ruan, G, Zanwar, S, Li, JJ, Sartori-Valinotti, JC, Snider, JN, Witzig, TE, Goyal, G, Go, RS, Abeykoon, JP. Personalized Medicine in Histiocytic Disorders. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 39576953.
- Bhutiani N, Seo YD, Robinson KA, White MG, Ikoma N, Mansfield PF, Li JJ, Murphy MB, Ajani JA, Badgwell BD. HIPEC for metastatic gastric cancer: Moving the needle towards 3-year survival. Eur J Surg Oncol 51(1):108790, 2024. e-Pub 2024. PMID: 39489042.
- Song Y, Hirata Y, Ajani JA, Blum Murphy M, Li JJ, Das P, Minsky BD, Mansfield PF, Ikoma N, Badgwell BD. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol 31(10):6918-6930, 2024. e-Pub 2024. PMID: 39048909.
- Badgwell B, Ikoma N, Blum M, Wang X, Estrella J, Liu X, Kawedia J, Li J, Mansfield P, Ajani J. Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology. Cancer, 2024. e-Pub 2024. PMID: 39287936.
- Sewastjanow-Silva M, Kwiatkowski E, Yamashita K, Abdelhakeem A, Yoshimura K, Vicentini ER, Pizzi MP, Jin J, Fan Y, Zou G, Wang L, Yin F, Dhar SS, Blum Murphy M, Mares JE, Li JJ, Gan Q, Waters RE, Rogers JE, Ajani JA. Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer, 2024. e-Pub 2024. PMID: 38995150.
- Yamashita K, Sewastjanow-Silva M, Yoshimura K, Rogers JE, Rosa Vicentini E, Pool Pizzi M, Fan Y, Zou G, Li JJ, Blum Murphy M, Gan Q, Waters RE, Wang L, Ajani JA. SMARCA4 Mutations in Gastroesophageal Adenocarcinoma: An Observational Study via a Next-Generation Sequencing Panel. Cancers (Basel) 16(7), 2024. e-Pub 2024. PMID: 38610978.
- Hogenson TL, Xie H, Phillips WJ, Toruner MD, Li JJ, Horn IP, Kennedy DJ, Almada LL, Marks DL, Carr RM, Toruner M, Sigafoos AN, Koenig-Kappes AN, Olson RL, Tolosa EJ, Zhang C, Li H, Doles JD, Bleeker J, Barrett MT, Boyum JH, Kipp BR, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Petersen GM, Dasari S, Oberg AL, Truty MJ, Graham RP, Levy MJ, Zhu M, Billadeau DD, Adjei AA, Dusetti N, Iovanna JL, Bekaii-Saab TS, Ma WW, Fernandez-Zapico ME. Culture media composition influences patient-derived organoids ability to predict therapeutic response in gastrointestinal cancers. JCI Insight, 2022. e-Pub 2022. PMID: 36256477.
- Ma WW, Li JJ, Azad NS, Lam ET, Diamond JR, Dy GK, Opyrchal M, Zhi J, Kramer D, Chan WK, Cutler D, Kwan R, Adjei AA, Jimeno A. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. Cancer Chemother Pharmacol 90(1):7-17, 2022. e-Pub 2022. PMID: 35731258.
- Li JJ, Zhang X, Sankar N, Espiritu L, Redkar S, Yu GL, Kizilbash SH. MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma. JCO Precis Oncol 6:e2200096, 2022. e-Pub 2022. PMID: 35675576.
- Li JJ, Kovach AR, DeMonia M, Slemmons KK, Oristian KM, Chen C, Linardic CM. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence. Sci Rep 11(1):16505, 2021. e-Pub 2021. PMID: 34389744.
- Li JJ, Chen W, Sadeghi N. Conjunctival lymphoma. BMJ Case Rep 12(7), 2019. e-Pub 2019. PMID: 31296640.
- Bhulani N, Gupta A, Gao A, Li J, Guenther C, Ahn C, Paulk E, Houck S, Beg MS. Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. J Gastrointest Oncol 9(3):495-502, 2018. e-Pub 2018. PMID: 29998015.
- Gupta A, Li J, Tawfik B, Pham T, Pathak S, Singh P, Porsa E, Sadeghi N, Li HC. Reducing Wait Time Between Admission and Chemotherapy Initiation. J Oncol Pract 14(5):e316-e323, 2018. e-Pub 2018. PMID: 29648922.
- Li J, Di C, Jing J, Di Q, Nakhla J, Adamson DC. OTX2 is a therapeutic target for retinoblastoma and may function as a common factor between C-MYC, CRX, and phosphorylated RB pathways. Int J Oncol 47(5):1703-10, 2015. e-Pub 2015. PMID: 26397460.
Review Articles
- Li JJ, Rogers JE, Waters RE, Gan Q, Blum Murphy M, Ajani JA. Evolution of Therapeutics for Locally Advanced Upper Gastrointestinal Adenocarcinoma. Cancers (Basel) 17(8):1307, 2025. e-Pub 2025. PMID: 40282483.
- Pabon, CM, Spieler, B, Li, JJ, Ajani, JA, Hosein, PJ, Murphy, MB. Is it time to retire preoperative radiation for localized esophageal and gastro-esophageal adenocarcinoma?. Oncologist 30(1), 2025. e-Pub 2025. PMID: 39846982.
- Li JJ, Rogers JE, Yamashita K, Waters RE, Blum Murphy M, Ajani JA. Therapeutic advances in the treatment of gastroesophageal cancers. Biomolecules 13(5), 2023. e-Pub 2023. PMID: 37238666.
- Li JJ, Zhu M, Kashyap PC, Chia N, Tran NH, McWilliams RR, Bekaii-Saab TS, Ma WW. The role of microbiome in pancreatic cancer. Cancer Metastasis Rev 40(3):777-789, 2021. e-Pub 2021. PMID: 34455517.
- Deel MD, Li JJ, Crose LE, Linardic CM. A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol 5:190, 2015. e-Pub 2015. PMID: 26389076.
- Mattox AK, Li J, Adamson DC. Stopping cancer in its tracks: using small molecular inhibitors to target glioblastoma migrating cells. Curr Drug Discov Technol 9(4):294-304, 2012. e-Pub 2012. PMID: 22339073.
- Li J, Di C, Mattox AK, Wu L, Adamson DC. The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med 3:111-27, 2010. e-Pub 2010. PMID: 23226047.
Abstracts
- Blum Murphy MA, Xiao L, Wang X, Sewastjanow-Silva M, Hofstetter WL, Swisher S, Mehran RJ, Mitchell KG, Bhutani MS, Weston B, Coronel E, Estrella J, Waters RE, Maru DM, Witt BJ, Li JJ, Yao JC, Ajani JA. Phase I-II trial of perioperative chemotherapy plus atezolizumab and tiragolumab in localized esophageal and gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology 44(2_suppl):418, 2026. e-Pub 2026.
- Staszewski H, Cortez E, Li G, Danziger N, Graf RP, Ross JS, Li JJ, Risch Z, Chen CT, Cohen DJ. Inferring optimal detection of MTAP homozygous loss (homozygous deletion) in gastric cancer: Associations with treatment exposure, disease site, and clinical outcomes. Journal of Clinical Oncology 44(2_suppl):327, 2026. e-Pub 2026.
- Fang J, Hanks ET, Li JJ, Blum Murphy MA, Ajani JA, Chang JY, Liao ZX, Nguyen Q, Hofstetter WL, Mitchell KG, Antonoff M, Walsh GL, Rice DC, Mehran RJ, Swisher S, Vaporciyan AA, Buchwald Z, Rajaram R, Lin SH, Qian D. Impact of time-of-day administration of neoadjuvant chemoradiotherapy on pathologic complete response in esophageal cancer: A multi-site review over two decades. Journal of Clinical Oncology 44(2_suppl):346, 2026. e-Pub 2026.
- Vinocha, A, Dasari, NV, Li, JJ, Thomas, J, Kopetz, S, Hu, Z, Shen, JY, Raghav, KS, Overman, MJ. Brain metastasis in patients with primary gastrointestinal malignancy on anti-HER2 therapy. Journal of Clinical Oncology 43:e16067-e16067, 2025. e-Pub 2025.
- Pabon, CM, Xiao, L, Badgwell, BD, Mansfield, PF, Ikoma, N, Sewastjanow-Silva, M, Lee, JH, Bhutani, M, Weston, B, Coronel, E, Smith, GL, Holliday, EB, Tian, J, Das, P, Minsky, B, Waters, R, Estrella, JS, Li, JJ, Ajani, JA, Blum Murphy, M. Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
- Ma WW, Ou FS, Li JJ, Tran NH, Babiker HM, Revzin A, Dong H, Nelson GD, Ness A, Schuster CE, Jia J, Bekaii-Saab TS, Academic A, Research United CC. ACCRU-GI-2008: A phase II randomized study of atezolizumab (Atezo) plus a multi-kinase inhibitor (MKI) versus MKI alone in patients with unresectable advanced hepatocellular carcinoma (aHCC) who previously received atezolizumab plus bevacizumab (Bev). Journal of Clinical Oncology 40(16_suppl), 2022. e-Pub 2022.
- Li JJ, Hsiao CL, Gao A, Syed SK, Unni N, Sadeghi N. Impact of dual anti-HER2 therapy on pathologic complete response rate in breast cancer in a minority-enriched population. J Clin Oncol 37(15_suppl), 2019. e-Pub 2019.
- Li JJ, Harper J, Zhu H, Bhulani N, Guenther CM, Madrigales A, Gates S, Kazmi SMA, Verma U, Toups M, Beg MS. Effective use of electronic medical record (EMR) data in analysis of association between KRAS mutations and depression in colorectal cancer patients. J Clin Oncol 36(suppl 4S), 2018. e-Pub 2018.
- Guenther CM, Bhulani N, Korenke A, Li JJ, Khosama L, Syed SK, Kazmi SMA, Cheedella NK, Karri S, Lohrey J, Sanjeevaiah A, Verma U, Cox JV, Arriaga YE, Beg MS. Prescribing patterns for FOLFIRINOX in the real world. J Clin Oncol 36(suppl 4S), 2018. e-Pub 2018.
- Bhulani N, Gao A, Gupta A, Chul A, Paulk ME, Houck S, Li JJ, Guenther CM, Kazmi SMA, Beg MS. Does timing of palliative care consults impact end-of-life health services utilization in pancreatic cancer patients?. J Clin Oncol 36(15_suppl), 2018. e-Pub 2018.
- Li JJ, Harper J, Bhulani N, Gerber DE, Khan SA, Madrigales A, Gates S, Toups M, Beg MS. Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients. J Clin Oncol 35(suppl 31S), 2017. e-Pub 2017.
Book Chapters
- Mattox A, Li J, Di C, Adamson DC. Medulloblastoma: Role of OTX2 Transcription Factors. In: Tumors of the Central Nervous System. 1. Springer, 47-58, 2012.
Web Publications
- Rajaram R, Li JJ. BMJ Best Practice, 2026.
Patient Reviews
CV information above last modified September 09, 2026